As home to the first FDA-approved cell and gene therapies Penn and Children’s Hospital of Philadelphia are international leaders who have helped propel Philadelphia into Cellicon Valley, with Penn ranking first among global universities for CAR-T cell patents according to Nature. CAR T represents a turning point in the history of human medicine, a genuine revolution in our approach to disease within the field of cellular therapy and transplant. The FDA approvals of chimeric antigen receptor (CAR) T cells offers even patients with highly chemo-refractory hematologic malignancies additional treatment options. World experts in cell and gene therapy and have been assembled to discuss the development and implementation of these therapies and to weigh in on current applications, best practices, novel strategies and future developments in this field.
Activity format will provide significant opportunity for interaction with expert faculty and other attendees with the aim of implementing new standards of patient care and understand new strategies to optimize and improve gene and cell therapies. Participants will leave with up-to-date, practical information which will have immediate clinical application, and an understanding of critical research initiatives that are rapidly driving this field forward, as well as the technical and scientific background on the current state, and where the latest scientific advances may take the field.
Related specialties: oncology, genetics